BPC 157: Experimental Peptide Creates Risk for Athletes The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Banned: Key Facts on the Latest FDA Decision Thousands of Sites, Less Than 100 Investigators: New Authorities Help FDA Maintain Oversight of Clinical Research FDA RFK Jr. and the Perils of Peptides Washington Monthly